Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety August 15, 2023 DOI: 10.1080/14740338.2023.2248883 via OpenAlex
Summary
AI-generated from the abstractThe text discusses concerns about psilocybin, lysergic acid diethylamide (LSD), and ecstasy in relation to valvular heart disease, focusing on 5HT2B receptor agonism and FDA guidance. It highlights the potential risk of these substances to cause heart valve damage through activation of the 5HT2B receptor, a mechanism linked to certain drugs. The abstract underscores regulatory considerations from the FDA regarding this safety issue, suggesting that agonism at this receptor may be a key factor in assessing the cardiac risks of psychedelic compounds.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Serotonin |
| Keywords | Medicine Agonism 5-HT Receptor Pharmacology |
| Citations | 26 |
| Key finding | Psilocybin, LSD, and ecstasy may pose a risk of valvular heart disease via 5HT2B receptor agonism, as noted in FDA guidance. |
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance